In agreement with previous findings, core AD biomarkers were associated with disease severity both in clinical diagnostic and clinico-pathological groups, with stepwise increases of p-tau 217, NfL and GFAP from cognitively unimpaired (CU) to dementia (p < 0.05). The gene discussed is MAPT; the disease is dementia.